Pharma Can Meet Cancer Patients’ and Oncologists’ Unique COVID-19 Needs

Posted by Jon Roffman on Mar 25, 2020 10:30:20 AM

Prashant Poddar co-wrote this blog post with Jon Roffman.

As the SARS-CoV-2 pandemic rages on, questions remain about how the virus is transmitted between people, how quickly it spreads and how contagious it is. But one thing is certain: The elderly and immunosuppressed patient populations, including those with cancer, are among the most at risk.

These patients need oncology manufacturers, healthcare providers and other stakeholders to ensure that they have continued access to care while minimizing exposure to the virus. Together, we can play a critical role in helping to improve and extend the lives of oncology patients. This should be our central focus today, knowing that it likely will change the way that we approach tomorrow and beyond.


>
Read More

Oncology 2020: From Invention to Outcomes

Posted by Jon Roffman on Mar 12, 2020 8:03:05 AM

Pranav Srivastava co-wrote this blog post with Jon Roffman. 

In the last three years alone, the FDA has given the green light to nearly 50 new cancer drugs. Were excited to see what 2020 has in store for this sector, as biopharma companies continue to bring these novel therapies and diagnostics to market. The fast pace of innovation in the oncology market presents increasingly complex challenges to manufacturers seeking to maximize the benefit that they can deliver to patientsWe’re committed to helping our client partnerand their customers thrive and ultimately improve outcomes for cancer patientsWith that in mind, our oncology practice is focused on three core dimensions that will be central to oncology manufacturers in the year ahead: navigating clinical pathways that drive the majority of treatment decisions in oncology; leveraging AI to deliver more relevant and valuable information to customers at the point of care; and delivering solutions that help customers better support their patients.


>
Read More

Changes in China Spark More External Oncology Drug Investments

Posted by Matt Furlow on Feb 19, 2020 8:00:00 AM

Bas Ludoph, Sonia Yan, Kelly Wang and Hannah Wang co-authored this post with Matt Furlow. 

China has become the world’s second largest pharmaceutical market (the US is No. 1), but novel drugs contribute to just a small fraction of that marketWhile there's great potential in China for novel drugsespecially those developed to treat cancer—it has  historically been a challenging market due to a difficult drug approval process, stringent market access policies and a complex healthcare ecosystem. Those factors have shifted over time and made China more amenable to external investmentsparticularly for novel oncology therapies.


>
Read More

Has the Amazon Prime of Cancer Genomic Profiling Arrived?

Posted by Pavankumar Anne on Dec 12, 2019 9:31:04 AM

Jim Adelizzi co-wrote this blog post with Pavankumar Anne.

The excitement behind precision medicine in oncology is impossible to ignore. Genomic profiling has enabled the greatest growth in precision medicine in oncology, and today there are 80-plus FDA-approved treatment options indicated for specific genetic markers. Innovations in next-generation sequencing (NGS) technology have further enabled advances in genomic profiling by increasing the speed, accuracy and affordability of sequencing. With this innovation comes a variety of options for testing:


>
Read More

Powering Up Your Oncology Patient Support Program

Posted by Rachael Pius on Nov 20, 2019 8:00:00 AM

Gila Allswang co-wrote this blog post with Rachael Pius.

As oncology patients and caregivers continue to play a more active role in their healthcare decisions and have more options available to them than ever before, many pharma companies are upping their investment in patient support programs. While patient-centered care can empower and engage patients by building their knowledge—and can often drive competitive differentiation—it’s also fraught with its own challenge: Oncology patients simply are not aware of the service offerings provided by manufacturers and are much less likely to use them. On average, only 46% of oncology patients and caregivers are aware of the offerings available to them, according to ZS’s recent survey on patient support programs. In many cases they may also find the offerings from other stakeholders in the health ecosystem to be more relevant to meet their needs. Further, oncology patients are offered support from many different players across the healthcare ecosystem—patient advocacy, specialty pharmacy, payers, hospital systems and pharmaceutical manufacturers are all offering patients support. There’s a high degree of overlap across the landscape, so it’s important for manufacturers to understand where patients are accessing support and why.


>
Read More